Serum levels of advanced glycation end products (AGEs) are independently correlated with circulating levels of dipeptidyl peptidase-4 (DPP-4) in humans

Clinical Biochemistry

Volumn 46, Issue 4-5, 2013, Pages 300-303

  Tahara, Nobuhiro ^a   Yamagishi, Sho ichi ^a   Takeuchi, Masayoshi ^b   Tahara, Atsuko ^a   Kaifu, Kumiko ^a   Ueda, Seiji ^a   Okuda, Seiya ^a   Imaizumi, Tsutomu ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

AGEs; DPP 4; Incretins

Indexed keywords

ADVANCED GLYCATION END PRODUCT; DIPEPTIDYL PEPTIDASE IV; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ANAMNESIS; ANTHROPOMETRIC PARAMETERS; ARTICLE; BLOOD CHEMISTRY; BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; KIDNEY TUBULE EPITHELIUM; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; OUTPATIENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; SEX DIFFERENCE; WESTERN BLOTTING;

AGED; BIOLOGICAL MARKERS; CELLS, CULTURED; CROSS-SECTIONAL STUDIES; DIPEPTIDYL PEPTIDASE 4; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; MIDDLE AGED;

EID: 84873737310     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.11.023     Document Type: Article

References (24)

1. Cordero O.J., Salgado F.J., Nogueira M. On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunol Immunother 2009, 58:1723-1747.
2. Yazbeck R., Howarth G.S., Abbott C.A. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?. Trends Pharmacol Sci 2009, 30:600-607.
3. Kim W., Egan J.M. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Res 2008, 60:470-512.
4. Yamagishi S., Matsui T. Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes. Curr Pharm Des 2011, 17:4379-4385.
5. Matsui T., Nishino Y., Takeuchi M., Yamagishi S. Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis. Pharmacol Res 2011, 63:383-388.
6. Maeda S., Matsui T., Yamagishi S. Vildagliptin inhibits oxidative stress and vascular damage in streptozotocin-induced diabetic rats. Int J Cardiol 2012, 158:171-173.
7. Iwaki-Egawa S., Watanabe Y., Kikuya Y., Fujimoto Y. Dipeptidyl peptidase IV from human serum: purification, characterization, and N-terminal amino acid sequence. J Biochem 1998, 124:428-433.
8. Stange T., Kettmann U., Holzhausen H.J. Immunoelectron microscopic single and double labelling to aminopeptidase N (CD 13) and dipeptidy peptidase IV (CD 26). Acta Histochem 1996, 98:323-331.
9. Schlatter P., Beglinger C., Drewe J., Gutmann H. Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul Pept 2007, 141:120-128.
10. Takeuchi M., Makita Z., Bucala R., et al. Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol Med 2000, 6:114-125.
11. Tahara N., Yamagishi S., Tahara A., et al. Serum level of pigment epithelium-derived factor is a marker of atherosclerosis in humans. Atherosclerosis 2011, 219:311-315.
12. Matsuo S., Imai E., Horio M., et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009, 53:982-992.
13. Yamagishi S., Inagaki Y., Okamoto T., et al. Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem 2002, 277:20309-20315.
14. Yamagishi S., Inagaki Y., Okamoto T., et al. Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells. Kidney Int 2003, 63:464-473.
15. Vallejo M.C., Matsuo A.L., Ganiko L., et al. The pathogenic fungus Paracoccidioides brasiliensis exports extracellular vesicles containing highly immunogenic α-Galactosyl epitopes. Eukaryot Cell 2011, 10:343-351.
16. Fukami K., Ueda S., Yamagishi S., et al. AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int 2004, 66:2137-2147.
17. Lamers D., Famulla S., Wronkowitz N., et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 2011, 60:1917-1925.
18. Nakamura K., Yamagishi S., Adachi H., et al. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes. Microvasc Res 2008, 76:52-56.
19. Schalkwijk C.G., Ter Wee P.M., Stehouwer C.D. Plasma levels of AGE peptides in type 1 diabetic patients are associated with serum creatinine and not with albumin excretion rate: possible role of AGE peptide-associated endothelial dysfunction. Ann N Y Acad Sci 2005, 1043:662-670.
20. Raucci A., Cugusi S., Antonelli A., et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 2008, 22:3716-3727.
21. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
22. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157.
23. Fonseca V., Schweizer A., Albrecht D., et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007, 50:1148-1155.
24. Yamaoka-Tojo M., Tojo T., Takahira N., et al. Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease. Cardiovasc Diabetol 2010, 9:17.